20/20 Biolabs Inc (NASDAQ:AIDX) Short Interest Update

20/20 Biolabs Inc (NASDAQ:AIDX) was the target of a large decrease in short interest in September. As of September 15th, there was short interest totaling 46,806 shares, a decrease of 50.4% from the August 31st total of 94,280 shares. Currently, 0.5% of the company’s stock are sold short. Based on an average daily volume of 58,991 shares, the days-to-cover ratio is currently 0.8 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised 20/20 Biolabs from a “sell (e-)” rating to a “sell (e)” rating in a report on Monday, August 3rd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $5.00.

20/20 Biolabs Price Performance

Shares of 20/20 Biolabs stock traded up $0.03 during trading on Tuesday, hitting $0.44. The stock had a trading volume of 8,899 shares, compared to its average volume of 438,580. The business has a fifty day moving average of $0.51 and a two-hundred day moving average of $1.00. 20/20 Biolabs has a fifty-two week low of $0.40 and a fifty-two week high of $50.00. The firm has a market cap of $5.57 million and a P/E ratio of -0.81.

20/20 Biolabs (NASDAQ:AIDX) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.26) EPS for the quarter. The business had revenue of $0.73 million for the quarter.

20/20 Biolabs Company Profile

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.